Navigation Links
Pharmasset to Present at Susquehanna's Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
Date:2/27/2008

PRINCETON, N.J., Feb. 27 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at Susquehanna Financial Group's Second Annual SIGnificant Investment Options in Healthcare Conference being held March 4-5, 2008 at the W Hotel in New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company on Wednesday, March 5, 2008 from 2:00 PM to 2:30 PM (ET) in the W Hotel's Sea/Ocean Room. In addition, Dr. Michelle Berrey, Pharmasset's Chief Medical Officer, and Dr. Michael Otto, Pharmasset's Chief Scientific Officer, will participate in a hepatitis C virus (HCV) therapeutic workshop, entitled "HCV: Polymerase Inhibitors" on Wednesday, March 5, 2008 from 9:15 AM to 10:15 AM (ET).

To access a simultaneous webcast of Mr. Price's overview of the company via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm. Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical co
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
9. Avicena Group to Present at Noble Financial Conference
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Strategic Diagnostics to Present at Two Upcoming Investor Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...fficacyendpointhasbeenmetforpatientswithadvanced-s...TY,Nov.24/PRNewswire-FirstCall/-AEternaZentarisInc...harmaceuticalcompanyfocusedonendocrinetherapyandon...e2studywithitstargetedcytotoxicpeptideconjugate,AE...urrentendometrialcancer.Inapersonalizedhealthcarea...
(Date:11/24/2009)...,Nov.24,2009/PRNewswire-FirstCall/--ArenaPharmaceu...ompanyisscheduledtopresentatthePiperJaffray21stAnn...EasternTime(8:30a.m.PacificTime)attheNewYorkPalace...hiefExecutiveOfficer,isscheduledtoprovideanovervie...scoveryprograms. ,, Aliveaudiowebcastoftheprese...
(Date:11/24/2009)... Program Connects Customers with Partners...d with DNA Genotek Products , ...Genotek , a leading provider of products for biolo...tion, today announced its new global partner progr...r DNA Genotek,s partner community and is designed ...
(Date:11/23/2009)...Y, Nov. 23, 2009 In a provocative new study, a Un...on dioxide emissions the major cause of global wa...nomy collapses or society builds the equivalent of...oks unlikely that there will be any substantial ne...ion in carbon dioxide emission rates," says the ne...
Breaking Biology Technology:AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4
...Inc. (Nasdaq: VIAP ), a biotechnology company fo...tment of cardiovascular and metabolic disease, tod...March 31, 2009, from the staff of the NASDAQ Stock...rently comply with NASDAQ Marketplace Rule 4310(c)...companies maintain either: (i) $2,500,000 in stock...
... for PACS data disaster recovery , , CHICAGO, Apr...siness unit of Siemens Healthcare ( www.sieme... www.harris.com ) are joining forces to offer h...for Picture Archiving and Communication Systems (P...ity. , , (Logo: http://www.newscom.com/cgi-b...
...all/ -- China Agri-Business, Inc.,(OTC Bulletin Bo...ral,application products through its operating com... the year ended December 31,2008. , Revenue fo...385, a,decrease of 3.8% as compared to $3,037,414 ... operations were adversely affected by natural and...
Other Biology Technology:VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 2VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 3VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 4Siemens Healthcare Announces Planned Collaboration with Harris Corporation 2Siemens Healthcare Announces Planned Collaboration with Harris Corporation 3Siemens Healthcare Announces Planned Collaboration with Harris Corporation 4China Agri-Business Announces 2008 Operating Results 2China Agri-Business Announces 2008 Operating Results 3China Agri-Business Announces 2008 Operating Results 4China Agri-Business Announces 2008 Operating Results 5
(Date:11/24/2009)...dge, Md. (November 24, 2009) New research on bact...r ecosystems reveals predictable temporal patterns...nities as markers for monitoring climate change in... in the Proceedings of the National Academy of Sc...ities in the six rivers shifted synchronously over...
(Date:11/23/2009)...gton, D.C. The community-associated strain of the... resistant to most common antibioticsposes a far g...making its way into hospitals, according to a stud...seases . , The new threat is easily picked up i...s and has increased the overall burden of MRSA wit...
(Date:11/23/2009)...w study by the Wildlife Conservation Society says ...amp in the Republic of Congopart of the "mother lo...yearare becoming increasingly threatened by growin...ommends protection of the swamp forests adjacent t... after recent surveys confirmed that high densitie...
Breaking Biology News(10 mins):Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New study finds MRSA on the rise in hospital outpatients 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Delirium in hospitalized adults 3A Situation critical no relief available 50777 1Delirium in hospitalized adults 3A Situation critical no relief available 50777 2Elderly breast cancer patients receive chemotherapy if treated in private practices 50775 1Elderly breast cancer patients receive chemotherapy if treated in private practices 50775 2Elderly breast cancer patients receive chemotherapy if treated in private practices 50775 3New Pre Clinical Data on OmniGuides BeamPath NEURO 28TM 29 Demonstrates Precise Cutting in Brain Tissue 12900 1New Pre Clinical Data on OmniGuides BeamPath NEURO 28TM 29 Demonstrates Precise Cutting in Brain Tissue 12900 2New Pre Clinical Data on OmniGuides BeamPath NEURO 28TM 29 Demonstrates Precise Cutting in Brain Tissue 12900 3
...an exceptional ability to spray venom into eyes of...ysiological and Biochemical Zoology reveals how t...target. , The name "spitting cobra" is a bit of a...s the study,s lead author Bruce Young, director of...ysical Therapy at the University of Massachusetts,...
...uary 22, 2009--Biotechnology companies are buildin...chniques over the past decade and are expected to ...rs, reports Genetic Engineering and Biotechnology...logy offers a number of advantages, including redu...lytical performance, multiparameter testing, and u...
...A patented Michigan State University process to pr...nol means extra nutrients don,t have to be added, .... , The AFEX (ammonia fiber expansion) pretreatme...stinguished Professor of chemical engineering and ...own of cellulose and hemicellulose in plants 75 pe...
Other Biology News:Here's venom in your eye: Spitting cobras hit their mark 2GEN reports on growing reliance on microfluidics technology 2Process can cut the cost of making cellulosic biofuels 2
miniDAWN from Wyatt Technology
Rabbit Complement from Equitech-Bio
Mouse Complement Lyophilized Powder from Equitech-Bio
Rabbit Complement Lyophilized Powder from Equitech-Bio
Biology Products: